Elsevier
Refine
Year of publication
Institute
- Fachbereich Medizintechnik und Technomathematik (183)
- INB - Institut für Nano- und Biotechnologien (105)
- IfB - Institut für Bioengineering (65)
- Fachbereich Chemie und Biotechnologie (57)
- Fachbereich Luft- und Raumfahrttechnik (35)
- Fachbereich Energietechnik (29)
- Fachbereich Maschinenbau und Mechatronik (16)
- Fachbereich Bauingenieurwesen (14)
- Solar-Institut Jülich (14)
- Fachbereich Elektrotechnik und Informationstechnik (9)
- Nowum-Energy (5)
- ECSM European Center for Sustainable Mobility (4)
- Fachbereich Wirtschaftswissenschaften (4)
- Institut fuer Angewandte Polymerchemie (4)
- Kommission für Forschung und Entwicklung (3)
- MASKOR Institut für Mobile Autonome Systeme und Kognitive Robotik (3)
- Sonstiges (3)
- Arbeitsstelle fuer Hochschuldidaktik und Studienberatung (1)
- Fachbereich Architektur (1)
- Freshman Institute (1)
- Kommission für Planung und Finanzen (1)
Has Fulltext
- no (350) (remove)
Document Type
- Article (328)
- Part of a Book (12)
- Conference Proceeding (9)
- Other (1)
Keywords
- Earthquake (4)
- LAPS (4)
- Gamification (3)
- Heparin (3)
- Central receiver power plant (2)
- Central receiver system (2)
- Chemometrics (2)
- Concentrated solar collector (2)
- Concentrated systems (2)
- Field-effect sensor (2)
Genetically humanized mice for proteins involved in drug metabolism and toxicity and mice engrafted with human hepatocytes are emerging as promising in vivo models for improved prediction of the pharmacokinetic, drug–drug interaction, and safety characteristics of compounds in humans. This is an overview on the genetically humanized and chimeric liver-humanized mouse models, which are illustrated with examples of their utility in drug metabolism and toxicity studies. The models are compared to give guidance for selection of the most appropriate model by highlighting advantages and disadvantages to be carefully considered when used for studies in drug discovery and development.
Mice that have been genetically humanized for proteins involved in drug metabolism and toxicity and mice engrafted with human hepatocytes are emerging and promising in vivo models for an improved prediction of the pharmacokinetic, drug–drug interaction and safety characteristics of compounds in humans. The specific advantages and disadvantages of these models should be carefully considered when using them for studies in drug discovery and development. Here, an overview on the corresponding genetically humanized and chimeric liver humanized mouse models described to date is provided and illustrated with examples of their utility in drug metabolism and toxicity studies. We compare the strength and weaknesses of the two different approaches, give guidance for the selection of the appropriate model for various applications and discuss future trends and perspectives.
An overview on dry low NOx micromix combustor development for hydrogen-rich gas turbine applications
(2019)
NVS123 is a poorly water-soluble protease 56 inhibitor in clinical development. Data from in vitro hepatocyte studies suggested that NVS123 is mainly metabolized by CYP3A4. As a consequence of limited solubility, NVS123 therapeutic plasma exposures could not be achieved even with high doses and optimized formulations. One approach to overcome NVS123 developability issues was to increase plasma exposure by coadministrating it with an inhibitor of CYP3A4 such as ritonavir. A clinical boost effect was predicted by using physiologically based pharmacokinetic (PBPK) modeling. However, initial boost predictions lacked sufficient confidence because a key parameter, fraction of drug metabolized by CYP3A4 (ƒₘCYP3A4), could not be estimated with accuracy on account of disconnects between in vitro and in vivo preclinical data. To accurately estimate ƒₘCYP3A4 in human, an in vivo boost effect study was conducted using CYP3A4-humanized mouse model which showed a 33- to 56-fold exposure boost effect. Using a top-down approach, human ƒₘCYP3A4 for NVS123 was estimated to be very high and included in the human PBPK modeling to support subsequent clinical study design. The combined use of the in vivo boost study in CYP3A4-humanized mouse model mice along with PBPK modeling accurately predicted the clinical outcome and identified a significant NVS123 exposure boost (∼42-fold increase) with ritonavir.